Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$20.6B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and success in commercializing its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies for various diseases. Operating in the healthcare sector, it aims to improve patient outcomes through its unique approach to drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Roivant's upcoming earnings are uncertain due to the lack of analyst estimates. Investors are keen to see if the company can maintain its recent momentum.

Bull Case

The optimistic view is that Roivant will continue to beat EPS expectations and show strong revenue growth, reflecting successful product development and market acceptance.

Bear Case

On the pessimistic side, there are concerns that the company may not sustain its previous performance, leading to disappointing results and a potential decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026, and how does it compare to previous quarters?

EPS is a key indicator of profitability, and a significant deviation from expectations could lead to a strong market reaction.

How much has Roivant invested in R&D this quarter?

R&D spending is crucial for a biotech company, and insights into this could indicate future growth potential and product pipeline strength.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Roivant's ability to leverage its recent successes into sustained profitability, especially given its innovative pipeline.

Supporting Evidence

Roivant has consistently surprised on EPS in recent quarters, indicating a trend of stronger-than-expected performance.

The options market is pricing a 10% move, suggesting traders expect significant volatility, which may not align with the company's recent stability.

Key Risk

If the EPS comes in below $0.20, it could undermine confidence in Roivant's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to build on its recent successes and maintain investor confidence.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case, suggesting challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests the stock could rise by an average of 9.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may react moderately, reflecting uncertainty.

Miss

If Roivant misses expectations, history indicates a potential decline of around 0.73%, which could raise concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the product pipeline and any upcoming launches.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into market demand for existing products.
4Any changes in R&D strategy or focus areas.
5Management's outlook on future earnings and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and success in commercializing its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Roivant's upcoming earnings are uncertain due to the lack of analyst estimates. Investors are keen to see if the company can maintain its recent momentum.

Bull Case

The optimistic view is that Roivant will continue to beat EPS expectations and show strong revenue growth, reflecting successful product development and market acceptance.

Bear Case

On the pessimistic side, there are concerns that the company may not sustain its previous performance, leading to disappointing results and a potential decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026, and how does it compare to previous quarters?

EPS is a key indicator of profitability, and a significant deviation from expectations could lead to a strong market reaction.

How much has Roivant invested in R&D this quarter?

R&D spending is crucial for a biotech company, and insights into this could indicate future growth potential and product pipeline strength.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Roivant's ability to leverage its recent successes into sustained profitability, especially given its innovative pipeline.

Supporting Evidence

Roivant has consistently surprised on EPS in recent quarters, indicating a trend of stronger-than-expected performance.

The options market is pricing a 10% move, suggesting traders expect significant volatility, which may not align with the company's recent stability.

Key Risk

If the EPS comes in below $0.20, it could undermine confidence in Roivant's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to build on its recent successes and maintain investor confidence.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case, suggesting challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$14.4M

489,774 sh

2 insiders

Net

$14.4M

Net selling

Most Active Insiders· 2 open-market trades

CEOGline Matthew
$8.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests the stock could rise by an average of 9.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may react moderately, reflecting uncertainty.

Miss

If Roivant misses expectations, history indicates a potential decline of around 0.73%, which could raise concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the product pipeline and any upcoming launches.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into market demand for existing products.
4Any changes in R&D strategy or focus areas.
5Management's outlook on future earnings and market conditions.